As global supply costs soar and the rupee depreciates, Sri Lanka’s pharmaceutical industry warns of an impending medical emergency, urging immediate government intervention to secure life-saving drugs.

Sri Lanka is teetering on the edge of a catastrophic public health emergency: the island nation, which has historically boasted a robust public healthcare system, is now facing a severe and worsening shortage of critical medicines and surgical equipment.

The crisis has been catalysed by a rapidly depreciating Sri Lankan rupee, an acute shortage of foreign currency reserves, and inflexible government price controls that have virtually paralyzed the import of essential medical supplies. According to the Sri Lanka Chamber of the Pharmaceutical Industry (SLCPI) and numerous medical trade unions, this situation has escalated from a sector-specific logistical challenge into a full-scale national threat.

Sri Lanka is heavily reliant on international markets for its healthcare needs, importing more than 85 per cent of its pharmaceuticals and nearly 80 per cent of its medical equipment. In ordinary economic conditions, the private pharmaceutical sector requires approximately $25 million to $30 million each month to maintain a consistent flow of medications into the country. However, the unprecedented depletion of Sri Lanka’s foreign exchange reserves has severely crippled this supply chain. Commercial banks are increasingly reluctant, or entirely unable, to open Letters of Credit (LCs) for importers due to the sheer lack of available US dollars.

Importers have found themselves trapped in an impossible financial predicament. Even when banking institutions attempt to facilitate these vital transactions, the sharp depreciation of the rupee against the US dollar has exponentially inflated the cost of purchasing these goods. Industry insiders report that banks frequently advise pharmaceutical importers to source dollars directly from exporters at steep premiums, bypassing the official pegged exchange rates. This practice drives the baseline cost of bringing medical cargo into the country far beyond sustainable limits, leaving many suppliers with no choice but to halt operations.

The Stranglehold of Strict Price Controls

Compounding the severe currency crisis is the country’s stringent regime of pharmaceutical price controls. Originally implemented to ensure that essential medications remained affordable for the general populace, these legally mandated price ceilings have ironically become one of the primary drivers of the current shortage. As domestic inflation skyrockets and the value of the rupee plunges, these price caps have not been adjusted rapidly enough to reflect economic realities.

Consequently, importing critical drugs has become commercially unviable. Overseas manufacturers and local vendors alike are forced to absorb catastrophic financial losses if they continue to import and distribute medicines under the current pricing regulations. Without swift regulatory adjustments, local suppliers are simply unable to restock their inventories, leading to the quiet disappearance of essential drugs from both state hospital pharmacies and private dispensaries.

Global Supply Chain and Bureaucratic Hurdles

The domestic economic turmoil is further exacerbated by immense global supply chain pressures. Transporting medicines requires highly regulated, temperature-controlled storage, secure handling, and timely import clearances. Recently, global freight charges have surged by over 40 per cent. Simultaneously, the global prices for active pharmaceutical ingredients (APIs), solvents, and vital packaging materials have climbed sharply – in some instances by up to 70 per cent. Domestic fuel prices have also risen by nearly 38 per cent, adding a massive logistical burden to the distribution of medicines across the island.

Bureaucratic bottlenecks have only added fuel to the fire. Importers are grappling with prolonged delays in import license renewals and sluggish pricing reviews by the National Medicines Regulatory Authority (NMRA). In a healthcare market like Sri Lanka’s, where order volumes are relatively modest and supply continuity relies heavily on predictable approval systems, even short regulatory delays can immediately translate into life-threatening stock limitations.

Hospitals and Patients Bear the Brunt

The real-world consequences of these intersecting crises are devastating. The Government Medical Officers’ Association (GMOA) and other prominent healthcare unions have sounded the alarm over hospitals running dangerously low on crucial items. Out of the roughly 7,300 medicines registered in the country, a significant and growing percentage is entirely out of stock. Patients suffering from chronic, life-threatening conditions such as cancer, kidney disease, diabetes, and hypertension are struggling daily to secure their prescribed treatments.

The shortages are not limited to oral medications. Essential consumables and life-saving injectables are also dwindling at an alarming rate. Medical professionals have reported severe shortages of anaesthesia, which has forced state hospitals to scale down or completely suspend non-essential and elective surgeries. In cardiology departments, critical items like stents, guide wires, catheters, and thrombolytic drugs – which are absolutely vital for dissolving blood clots during heart attacks – are in precariously short supply. In maternity and paediatric wards, doctors have faced shortages of the breathing tubes required for premature newborns, leading to desperate appeals for intervention.

Calls for Immediate Action and Sustainable Solutions

While international charitable organizations and foreign aid have provided some temporary relief through donations of medicine and supplies, experts agree that short-term charity cannot replace a functioning national pharmaceutical supply chain. The consensus among healthcare professionals, trade unions, and industry leaders is clear: urgent, coordinated government action is required to avert a full-scale humanitarian disaster.

The SLCPI has presented a comprehensive roadmap for immediate relief. Their demands include prioritizing foreign exchange allocations specifically for life-saving pharmaceuticals, urgently addressing the bureaucratic delays in import license processing, and significantly revising the strict price control mechanisms to reflect the stark realities of current exchange rates and soaring global freight costs.

SLCPI spokespersons say that without swift and decisive interventions to stabilize the supply chain and restore the financial viability of drug imports, Sri Lanka risks sliding into a catastrophic scenario where medicine shortages become chronic, widespread, and increasingly fatal.